AstraZeneca
This study will evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single ascending doses (SAD) and multiple ascending doses (MAD) of AZD4248 administered as an oral solution and intravenous (IV) infusion. Additionally, the study investigates the non-interventional feasibility of home measurement of serum creatinine in participants with diabetic kidney disease (DKD), and the effect of multiple doses of AZD4248 on the PK of oral midazolam and metformin.
This is a Phase I, first in human (FIH), randomized, single-blind, placebo-controlled study of AZD4248 involving healthy participants (Parts A and B) and participants with DKD (Part C), to assess home measurements of creatinine in a prospective, non-interventional cohort in participants with DKD (Part D), and assess the effect of multiple doses of AZD4248 on the PK of oral midazolam and metformin in an open-label, fixed sequence design in healthy participants (Part E). The study consists of 5 parts: * Part A: SAD. Part A will consist of Parts A1 (single ascending doses in healthy participant…
Key Inclusion Criteria: \- Healthy participants with suitable veins for cannulation or repeated venipuncture. Parts A, B, and E: * Have a body mass index (BMI) between 18 and 30 kilograms per millimeter (kg/m2), inclusive. * For Chinese participants (Part A2): participants are to be Chinese, defined as having both parents and 4 grandparents who are Chinese. This includes second and third generation participants of Chinese descent whose parents or grandparents are living in a country other than China. * For Japanese participants (Part B2): participants are to be Japanese, defined as having b…
AZD4248 will be administered orally.
Placebo will be administered orally.
AZD4248 will be administered via IV infusion.
Placebo will be administered via IV infusion.
Midazolam will be administered orally.
Metformin will be administered orally.